BioNTech and CureVac have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire, in an all-stock transaction, all of the shares of CureVac.  

Under the terms of the Purchase Agreement, each CureVac share will be exchanged for approx. USD 5.46 in BioNTech ADSs, resulting in an implied aggregate equity value for CureVac of approx. USD 1.25 billion. Upon closing of the transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech.

This acquisition will strengthen the research, development, manufacturing and commercialisation of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in the execution of its oncology strategy.

Our lawyers and tax advisers assisted on the corporate, tax, employment and capital markets aspects of the transaction. CureVac and its subsidiaries will experience some corporate reorganisation following the closing of the exchange offer which will transfer 100% ownership of both business and interests to BioNTech.

Biopharmaceutical New Technologies – known as BioNTech, is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases.

CureVac is a pioneering multinational biotech company founded in 2000 to advance the field of messenger ribonucleic acid (mRNA) technology for application in human medicine. This clinical-stage biotech company is developing a novel class of transformative medicines in oncology and infectious diseases based on mRNA.

For more information, do not hesitate to contact one of the advisers on the matter.